New blood test measures Alzheimer's progression
ALMR•A blood test from Alamar Biosciences measures eMTBR-tau, a biomarker of tau-tangle buildup in the brain, but is not yet available for clinical use. Separate research found that cerebrospinal fluid flow during sleep often declined in older volunteers.
1. Blood test tracks progression
A blood test from Alamar Biosciences measures eMTBR-tau, a biomarker that reflects the extent of tau-tangle buildup in brain cells. The test is not yet available for clinical use and is not intended to diagnose Alzheimer's disease on its own. Researchers said it could complement existing blood tests to help doctors make treatment decisions and identify patients for clinical trials.
2. Aging and brain fluid flow
In a study of volunteers ages 18-39 and 60-84, researchers found that the brain waves and cerebrospinal fluid waves associated with waste removal during non-REM sleep became stronger in younger adults, but not consistently in older participants. Reduced blood-flow responses explained much, but not all, of the age-related decline in cerebrospinal fluid flow. Some older participants showed gray matter atrophy correlated with a greater decrease in fluid flow; none had been diagnosed with a neurodegenerative disorder.




